Design of substrate-based BCR-ABL kinase inhibitors using the cyclotide scaffold

The constitutively active tyrosine kinase BCR-ABL is the underlying cause of chronic myeloid leukemia (CML). Current CML treatments rely on the long-term use of tyrosine kinase inhibitors (TKIs), which target the ATP binding site of BCR-ABL. Over the course of treatment, 20–30% of CML patients devel...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yen-Hua, Henriques, Sónia T., Wang, Conan K., Thorstholm, Louise, Daly, Norelle L., Kaas, Quentin, Craik, David J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532999/
https://www.ncbi.nlm.nih.gov/pubmed/26264857
http://dx.doi.org/10.1038/srep12974

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532999/
https://www.ncbi.nlm.nih.gov/pubmed/26264857
http://dx.doi.org/10.1038/srep12974

Ejemplares similares